ClinicalTrials.gg

Hyperlipoproteinemia Type II clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 249 studies for Hyperlipoproteinemia Type II across more than 10 countries. 56 are recruiting or about to start. 164 of them are mainly about Hyperlipoproteinemia Type II (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Homozygous Familial Hypercholesterolemia too: 295 studies, 64 open.

Status

Completed
139
Recruiting
36
Status unknown
27
Not yet recruiting
14
Terminated
14
Active, not recruiting
9

Phase

Phase 3
68
Phase 2
37
Phase 1
19
Phase 4
13
Early Phase 1
6

Where

United States
76
Canada
43
Netherlands
35
United Kingdom
27
China
24
Norway
22

Who develops what

Add Hyperlipoproteinemia Type II to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 10 programs from 8 companies, 9 with this as their studies’ main aim; 5 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Arrowhead Pharmaceuticals, CSPC Pharmaceutical Group and Daiichi Sankyo here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
inclisiranRecent, limited
Evidence
  • NCT07421232 · CSPC Pharmaceutical Group Limited · Phase 2 · comparator · “Inclisiran (Leqvio®) 300mg” · registered Feb 2026
Novartis97% of its industry studiesUS: Novartis (FDA 2021)EU: Novartis (EMA 2020)11 study
AtorvastatinEarlier only
Evidence
  • NCT01956201 · Chong Kun Dang Pharmaceutical · Phase 3 · background · “Atorvastatin 20mg” · registered Sep 2013
  • NCT01279590 · AbbVie · Phase 2 · comparator · “Atorvastatin” · registered Jan 2011
  • NCT00289900 · Merck & Co., Inc · Phase 3 · comparator · “Atorvastatin” · registered Feb 2006
Viatris Inc.16% of its industry studiesUS: off-patent, 23 generics marketed00 studies
SimvastatinEarlier only
Evidence
  • NCT01362218 · Ferrer Internacional S.A. · Phase 2 · comparator · “Simvastatin, ramipril, acetylsalicylic acid” · registered May 2011
  • NCT01004705 · Ferrer Internacional S.A. · Phase 2 · comparator · “Simvastatin” · registered Oct 2009
  • NCT00289900 · Merck & Co., Inc · Phase 3 · background · “Simvastatin” · registered Feb 2006
Organon & Co.29% of its industry studiesUS: off-patent, 10 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
QLC7401☆ Track3 live phase-3 studies: NCT07450378, NCT07441317, NCT07444086Qilu Pharmaceutical Co., Ltd.
SYH2053☆ Track2 live phase-3 studies: NCT07465263, NCT07421297CSPC Pharmaceutical Group Limited
lerodalcibepApproved: US 2025☆ Track2 live phase-3 studies: NCT07775339, NCT04798430LIB Therapeutics LLC
enlicitide decanoateApproved: US 2026☆ Track1 live phase-3 study: NCT07058077Merck & Co., Inc

The 4 in phase 3 with the nearest primary completion, of 10 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Apr 2027 est.SYH2070 · CSPC Pharmaceutical Group Limited · Phase 2 main aimNCT07695597 A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia — primary endpoint: The percentage change in serum TG levels from baseline at week 24 · 240 enrolled
  • Jul 2027 est.ARO-DIMERPA · Arrowhead Pharmaceuticals · Phase 2 main aimNCT07223658 Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia — primary endpoint: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) · 78 enrolled
  • 7 Oct 2027 est.QLC7401 · Qilu Pharmaceutical Co., Ltd. · Phase 3 main aimNCT07444086 QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia — primary endpoint: Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) from Baseline · 510 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hyperlipoproteinemia Type II studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here PCSK9 inhibitors 2 open · Statins 17

Coming up

15studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger. 17 (47%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (14%) take healthy volunteers.

Recruiting studies that take each age, of 36
AgeWomenMen
1014 (39%)14 (39%)
1829 (81%)29 (81%)
3026 (72%)26 (72%)
4027 (75%)27 (75%)
5028 (78%)28 (78%)
6527 (75%)27 (75%)
7522 (61%)22 (61%)
8520 (56%)20 (56%)

Across all 249 studies, recruiting or not: 39% stop at 75 or younger and 24% at 65; 30% take children; 1% are for women only and 1% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hyperlipoproteinemia Type II studies take

Of 33 phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 323 mo18–34 · 33 studies23 mo18–34 · 29 studies—
Interventional, no phase29 mo12–51 · 37 studies—37 mo12–51 · 35 studies
Observational71 mo23–82 · 32 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 249. Browse all 249 → or search them.